N/A
N=60
Non-invasive Cooling of Subcutaneous Fat
Fat Disorder
Bottom Line
View on ClinicalTrials.gov: NCT00762307 ↗Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcome: Primary: Change in Fat Layer Thickness of the Treated Flank — -18.7; -22.6; -17.8; -17.5 percent fat layer change
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Zeltiq Dermal Cooling Device (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Zeltiq Aesthetics
- Primary completion
- Jan 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Fat Layer Thickness of the Treated Flank |
-18.7; -22.6; -17.8; -17.5; -11.1 | — |
| PRIMARY Percentage of Subjects Expressing Satisfaction With the Procedure |
82.1; 84; 81.8; 90.9; 66.7; 76.3 | — |
| PRIMARY Percentage of Correctly Identified Pre-treatment Photographs |
91.9; 90.5; 100; 100; 83.3 | — |
Summary
The purpose of this study is to evaluate a non-invasive cooling device to determine if cold exposure will consistently result in a reduction of subcutaneous fat.
Eligibility Criteria
Inclusion Criteria
- Male or female subjects > 18 years of age.
- Subject has clearly visible fat on the flanks, thighs, abdomen, or back.
- Subject has not had weight change fluctuations exceeding 10 pounds in the preceding month.
- Subject has read and signed a written informed consent form.
Exclusion Criteria
- Subject has had liposuction, or another surgical procedure(s) or mesotherapy in area of intended treatment within the past 2 years.
- Subject has a known history of subcutaneous injections into the area of intended treatment (e.g., cortisone) within the past 6 months.
- Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria.
- Subject is taking diet pills within the past 6 months.
- Subject is unable or unwilling to comply with the study requirements.
- Subject has any dermatological conditions or scars within the location of the test sites that may interfere with the treatment or evaluation.
- Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.
- Patient is pregnant or intending to become pregnant in the next 9 months.
- Patient is lactating or has been lactating in the past 9 months.
- Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.
Data sourced from ClinicalTrials.gov (NCT00762307). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.